DDInter500 DDInter131
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy and 2 light chains, with each light chain consisting of 215 amino acids and each heavy chain consisting of 448 amino acids with 4 intramolecular disulfides. Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis in postmenopausal women. It further received additional indication approval to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer and women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer in September
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
Denosumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Denosumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Durvalumab
Denosumab {u} may lead to a major life threatening interaction when taken with {v} Etelcalcetide
Denosumab {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab
Denosumab may lead to a major life threatening interaction when taken with Etelcalcetide
Denosumab may lead to a major life threatening interaction when taken with Cladribine